Clinical Trial Search

Primary: Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery

Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…

Primary: Objective Response Rate

Primary: Completeness of Cytoreduction

Primary: Number of Participants With Disease-free Survival

Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index

Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants

Primary: Response Assessment — 0; 0; 0; 0 Participants

Primary: Best Response — 0; 7; 11; 11 participants

Primary: Progression Free Survival

Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants

Primary: Disease Control Rate (DCR) — 75 percentage of participants

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: 24 Week Progression Free Survival — 23 percentage of participants

Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants

Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants

Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months

Primary: Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) — 4; 0; 0; 1 Participants

Primary: Overview of Adverse Events — 28; 23; 12; 1 participants

Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants

Primary: Progression-free Survival — 3.0; 3.4 months

Primary: Number of Participants With an Objective Response — 1; 0; 0; 0 Participants

Primary: Disease Control Rate at 4 Months — 8 Participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…

Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76

Primary: Overall Response Rate — 9 percentage of participants

Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109

Primary: Recurrence Free Survival — 13.99 months